Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7%

Key Points

• Short interest rose 51.7% in April to 587,281 shares (about 5.9% of the float), with a short-interest ratio of roughly 0.3 days given high average daily volume.
• Institutional investors own ~75% of ImageneBio, and several firms (including Atlas Venture Life Science, Blue Owl, BML Capital, Aldebaran and Jane Street) established new stakes in recent quarters.
• Analyst consensus is a Hold (1 Strong Buy, 1 Hold, 2 Sell) with a consensus price target of $26.50, compared with the recent share price near $5.83.

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totaling 587,281 shares, an increase of 51.7% from the March 31st total of 387,034 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,776,149 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of ImageneBio

A number of institutional investors have recently made changes to their positions in the stock. Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio in the third quarter worth approximately $3,079,000. BML Capital Management LLC bought a new stake in ImageneBio during the 3rd quarter valued at $1,487,000. Blue Owl Capital Holdings LP bought a new stake in ImageneBio during the 3rd quarter valued at $4,409,000. Aldebaran Capital LLC purchased a new stake in ImageneBio during the 3rd quarter valued at $159,000. Finally, Jane Street Group LLC purchased a new stake in ImageneBio during the 4th quarter valued at $103,000. Hedge funds and other institutional investors own 75.00% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of ImageneBio from a "strong sell" rating to a "hold" rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, ImageneBio presently has an average rating of "Hold" and a consensus price target of $26.50.

ImageneBio Trading Up 2.1%

IMA opened at $5.83 on Tuesday. The company has a market cap of $62.09 million, a P/E ratio of -0.72 and a beta of 0.55. The business's 50-day moving average price is $5.80 and its 200-day moving average price is $6.67. ImageneBio has a 12 month low of $3.94 and a 12 month high of $18.00.

ImageneBio (NASDAQ:IMA - Get Free Report) last issued its earnings results on Tuesday, March 10th. The company reported $0.34 earnings per share for the quarter. Equities research analysts forecast that ImageneBio will post -2.98 earnings per share for the current fiscal year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.